Scott Chan

Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.

Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.

Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.

Analyst Articles

Sell to close the PowerShares DB U.S. Dollar Index Bullish Fund (NYSE: UUP) December 15, 2017 $25 call option. Sell to close the VanEck Vectors Gold Miners ETF (NYSE: GDX) December 15, 2017 $23 put option. We recommend taking the modest gains… Read More

Heading into this week’s Federal Open Market Committee meeting, most expected another rate hike, and the Fed delivered. With one dissenter, the committee voted to up the target federal funds rate to a range of 1 to 1.25 percent. This marks the fourth quarter-percentage point rate increase since the Financial… Read More

On Wednesday, we recommended buying to open the PowerShares DB US Dollar Index Bullish Fund (NYSE: UUP) December 15, 2017 $25 call option. Our dollar indicator became bullish enough to warrant going long the dollar.  At the same time, we recommended buying to close the CurrencyShares Japanese Yen Trust… Read More

Sell to close the CurrencyShares Japanese Yen Trust (NYSE: FXY) July 21, 2017 $90 call option. Buy to open the PowerShares DB U.S. Dollar Index Bullish Fund (NYSE: UUP) December 15, 2017 $25 call option. We suggest paying no more than 60 cents per contract. We… Read More

Biotech Theravance Biopharma (Nasdaq: TBPH) this week reported another piece of good clinical data. The company reported that multiple studies conducted on VIBATIV—currently its only marketed drug—showed superior in vitro potency for VIBATIV against the S. aureus pathogens compared to other commercially available antibiotics. VIBATIV is already approved to treat S. aureus, but the company hopes the studies will differentiate it from competing antibiotics. Read More

Yesterday we recommended buying to open a position in the CurrencyShares Japanese Yen ETF (NYSE: FXY) July 21, 2017 $90 call option, at a suggested limit price of 55 cents. As noted in the Trade Alert, this is not an indicator-based trade. The trade is intended as a short-term hedge… Read More

After a weak March, then a strong April, U.S. hiring activity again fell lower than expected in May. Today’s Labor Department monthly report shows that non-farm payrolls only increased by 138,000, well below the 182,000 consensus economist projection. Furthermore, the estimates for March and April were revised downward by a… Read More